Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers
The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and regardless of BRCA mutations. The new formulation of Lynparza as tablets — marketed by AstraZeneca and Merck (MSD outside North America) — was approved to treat high-grade epithelial ovarian, fallopian tube (tube that connects the ovaries to the uterus), or primary cancer of the peritoneum (the membrane lining the abdomen). This  formulation is also approved by the U.S. Food and Drug Administration (FDA) to treat advanced ovarian cancer and certain types of metastatic breast cancer. European approval follows a
Subscribe or to access all post and page content.